Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial... see more

Recent & Breaking News (NYSE:EBS)

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00

Marketwired September 24, 2015

Emergent BioSolutions Receives $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous Program

GlobeNewswire August 13, 2015

Emergent BioSolutions Announces Plan to Implement Tax-Free Spin-Off of Biosciences Business Into a Separate Publicly-Traded Company

GlobeNewswire August 6, 2015

Emergent BioSolutions Reports Second Quarter and Six Months 2015 Financial Results and Reaffirms 2015 Guidance

GlobeNewswire August 6, 2015

Emergent BioSolutions Expands Biodefense Business Through Launch of a Military-Grade Auto-Injector Device for Chemical Threats

GlobeNewswire August 3, 2015

Emergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call on August 6, 2015

GlobeNewswire July 23, 2015

Emergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call on August 6, 2015

GlobeNewswire July 23, 2015

Emergent BioSolutions Awarded $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal Antibodies

GlobeNewswire July 20, 2015

Emergent BioSolutions Awarded $19.7 Million BARDA Contract to Develop and Manufacture Ebola Monoclonal Antibodies

GlobeNewswire July 20, 2015

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00

Marketwired May 21, 2015

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00

Marketwired May 21, 2015

Emergent BioSolutions Signs Long-Term Manufacturing Agreement With Prometic Life Sciences

GlobeNewswire May 19, 2015

Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 21, 2015 at 9:00 AM Eastern; Webcast Will be Available

GlobeNewswire May 14, 2015

Oxford University, GSK, and Emergent BioSolutions Announce Initiation of a Prime Boost Study of Ebola Vaccine Candidates

GlobeNewswire May 13, 2015

Emergent BioSolutions Reports First Quarter 2015 Financial Results

GlobeNewswire May 7, 2015

Emergent BioSolutions Expands Commercial Product Portfolio With FDA Approval of IXINITY, a Recombinant Factor IX Treatment for Hemophilia B

GlobeNewswire April 30, 2015

Emergent BioSolutions to Participate in May and June 2015 Investor Conferences

GlobeNewswire April 29, 2015

Emergent BioSolutions Completes Investigation and Resumes BioThrax Manufacturing Activities; Re-Affirms Previous Full-Year 2015 Financial Outlook

GlobeNewswire April 22, 2015

Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in the Treatment of Inhalational Anthrax

GlobeNewswire March 25, 2015

Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine

GlobeNewswire March 24, 2015